TopGear Automation — Department of Defense SBIR Phase II: TopGear Automation"s Phase I program successfully demonstrated the feasibility of a n

Description

TopGear Automation"s Phase I program successfully demonstrated the feasibility of a new approach for the discovery of biomarkers that detect exposure to toxicants with greater sensitivity and specificity. This innovation promises to provide an effective solution for specific Force Health Protection defenses. Phase I results showed that the algorithm is suitable for use across a wide range of datasets and platforms. The goal for Phase II is to develop, test, and deliver a software application based on the Phase I algorithm that identifies compact gene signatures to accurately identify toxicants. Our leadership team is experienced in program management, clinical guidance, and commercialization. TopGear"s market strategy is to capitalize on the emerging demand for biomarkers and biomarker analysis by focusing on generating revenue from innovative software capabilities. The worldwide market opportunity for biomarkers is projected to top $34B by 2017. The company"s revenue projections show that by year 5 the total revenue for just one segment will exceed $19M. This represents approximately 21% of the initial launch market and secures the company as a competitive player. The market capital requirements are low since the company intends to partner with major hardware and reagent providers for the initial launch of the product.